In 5subjects with type 2 diabetes uncontrolled on metformin and basal insulin, the DUAL VII trial (NCT02420262) demonstrated that a once-daily injection of insulin degludec/liraglutide (IDegLira) was non-inferior to multiple injections of basal-bolus therapy (insulin glargine 100 units/mL + insulin aspart before each main meal) for A1C reduction, and was associated with a significantly lower risk of hypoglycemia. This non-prespecified post-hoc analysis examined whether the efficacy results persisted across sub-groups for six different variables and evaluated whether benefits seen in the trial were applicable across a broad patient population. After 26 weeks of treatment, there was no significant difference in A1C reduction between IDegLira compared with basal-bolus in any baseline characteristic group (A1C, BMI, age, diabetes duration, total daily insulin dose and fasting plasma glucose [Table]). Additionally, there was no significant interaction between treatment and baseline sub-group for any of the baseline characteristics (Table).
In conclusion, the A1C lowering was comparable between once-daily IDegLira vs. basal-bolus therapy after 26 weeks of treatment, irrespective of baseline characteristics, which underscores the general application of these findings to a broad patient population.
L.K. Billings: Advisory Panel; Self; Novo Nordisk A/S, Sanofi. Consultant; Self; Novo Nordisk A/S. Research Support; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S, Dexcom, Inc. D.C. Klonoff: Consultant; Self; Ascensia Diabetes Care, Lifecare, Intarcia Therapeutics, Inc., Voluntis USA, Novo Nordisk Inc., Onduo, Trividia Health, Inc., American Diabetes Association, The Endocrine Society, American Association of Diabetes Educators. N. Tentolouris: Advisory Panel; Self; MSD K.K., AstraZeneca, Sanofi, Novo Nordisk A/S, Elpen Pharmaceutical Co. Inc., Eli Lilly and Company, Boehringer Ingelheim GmbH, Novartis AG. Research Support; Self; MSD K.K., Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Pfizer Inc., AstraZeneca, Janssen-Cilag Pty Limited, GlaxoSmithKline plc., Novartis AG. R. Grøn: Employee; Self; Novo Nordisk A/S. N. Halladin: Employee; Self; Novo Nordisk A/S. E. Jódar: Advisory Panel; Self; Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S. Research Support; Self; Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Pfizer Inc., Sanofi. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S.
